| Name | Title | Contact Details |
|---|
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.
MicroConstants is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.
Precision BioSciences is a publicly held biotechnology company dedicated to improving life through its next generation gene editing technology, ARCUS. Precision`s cell therapy, gene therapy, and agriculture programs are based on the proprietary ARCUS gene editing platform, which features coordinated target site binding and DNA cutting to ensure precise edits. Our team includes pioneers in genome engineering, biotech business leaders, and a growing staff of committed Precisioneers. We work together in our beautifully designed, award-winning space in vibrant downtown Durham, NC; a place with great restaurants and museums as well as fantastic housing and schools. Precision provides all employees a sense of purpose, thoughtfully designed laboratory and office spaces, and opportunities to train and grow – not to mention plentifully stocked kitchens and fantastic benefits. At Precision BioSciences, we are excited to work together toward improving lives by realizing the potential of gene editing.
Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.